

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) An isolated polypeptide comprising the an amino acid sequence  
~~selected from the group consisting of:~~
  - ~~(a) — a mature form of an amino acid sequence selected from the group~~  
~~consisting of SEQ ID NO: 2, 5, 7, 66 and 68;~~
  - ~~(b) — a variant of a mature form of an amino acid sequence selected from the~~  
~~group consisting of SEQ ID NO: 2, 5, 7, 66 and 68 wherein one or more amino acid~~  
~~residues in said variant differs from the amino acid sequence of said mature form,~~  
~~provided that said variant differs in no more than 15% of the amino acid residues from~~  
~~the amino acid sequence of said mature form;~~
  - ~~(c) — an amino acid sequence selected from the group consisting of SEQ ID~~  
~~NO: 2, 5, 7, 66 and 68; and~~
  - ~~(d) — a variant of an amino acid sequence selected from the group consisting of~~  
~~SEQ ID NO: 2, 5, 7, 66 and 68 wherein one or more amino acid residues in said variant~~  
~~differs from the amino acid sequence of said mature form, provided that said variant~~  
~~differs in no more than 15% of amino acid residues from said amino acid sequence.~~
2. (Amended herein) An isolated polypeptide comprising The polypeptide of claim 1,  
~~wherein said polypeptide comprises the amino acid sequence of a naturally-occurring~~  
~~allelic variant of the an amino acid sequence selected from the group consisting of SEQ~~  
~~ID NO: 2, 5, 7, 66 and 68, wherein said variant comprises an amino acid sequence that is~~  
~~the translation of a nucleic acid sequence differing by a single nucleotide from the~~  
~~nucleic acid sequence of SEQ ID NO: 65.~~
3. (Canceled).
4. (Currently Amended) The polypeptide of claim 2 ~~1~~, wherein the amino acid sequence of  
said variant comprises a conservative amino acid substitution.
- 5-26. (Canceled).

27. (Currently Amended) A method of treating or preventing a NOV<sub>4</sub>-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said NOV<sub>4</sub>-associated disorder in said subject.
28. The method of claim 27, wherein said subject is a human.
- 29-32. (Canceled).
33. (Currently Amended) A ~~pharmaceutical~~ composition comprising the polypeptide of claim 1 and a ~~pharmaceutically-acceptable~~ carrier.
- 34-35. (Canceled).
36. (Currently Amended) A kit comprising in one or more containers, the ~~pharmaceutical~~ composition of claim 33.
- 37-38. (Canceled).
39. (Currently Amended) A method of manufacturing a medicament having a therapeutic for treating a syndrome associated with a human disease, the disease selected from a NOV-associated disorder, wherein said therapeutic is selected from the group consisting of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:66, or an isolated polypeptide comprising the amino acid sequence of a naturally-occurring variant of the amino acid sequence of SEQ ID NO: 66, wherein said variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from the nucleic acid sequence of SEQ ID NO: 65 wherein said polypeptide variant has kinase activity.
- 40-48. (Canceled).
49. (New) The method of claim 27, wherein said NOV-associated disorder is breast cancer.
50. (New) An isolated polypeptide comprising an amino acid sequence at least 96% identical

Applicants: Prayaga et al.  
U.S.S.N. 09/973,424

to SEQ ID NO: 66, wherein said polypeptide has kinase activity.

### REMARKS

In response to the Office Action Dated August 12, 2003, Applicants elect the invention of group I, (claims 1-4, 27-28, 33, 36, 29 and 47, drawn to isolated polypeptides and the therapeutic use of said polypeptides *in vivo*). Applicants further elect SEQ ID NO: 66.


Upon entry of this amendment, claims 1, 2, 4, 27-28, 33, 36, 39 and 49-50 will be pending. Claims 3, 5-26, 29-32, 34-5, 37-8 and 40-8 have been canceled without prejudice or disclaimer, claims 1, 2, 4, 27, 33, 36, and 39 have been amended, and new claims 49-50 have been added herein. Support for the amendment to claim 2 can be found in originally filed claim 3. Support for the amendment to claim 39 can be found in originally filed claims 2 and 3 and the specification at, *e.g.*, page 14, lines 24-26. Support for new claim 49 can be found in the specification at, *e.g.*, page 28, lines 16-23. Support for new claim 50 can be found in originally filed claim 1 and the specification at, *e.g.*, Table 6 on page 16, line 40 to page 17, line 58. No new matter has been added.

### CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

September 12, 2003

Respectfully submitted,

  
Ivor R. Enfi, Reg. No. 39,529  
Naomi S. Biswas, Reg. No. 38,384  
Cynthia A. Kozakiewicz, Reg. No. 42,764  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623